益气活血解毒法对慢性心力衰竭炎症状态的研究
|
摘要
慢性心力衰竭,是各种心血管疾病由于长期负荷过重、心肌损害及收缩力减弱所致的心功能不全(失代偿期)的一种复杂综合征,是众多心脏疾病的终末阶段,死亡率极高。对心力衰竭发生发展机制的研究一直是全球心血管病防治的重点。一个世纪以来,心衰理论经历心肾学说、血流动力学学说、神经内分泌激素学说到现代的心室重构学说。现代分子生物学研究认为有关心衰的病理、生理机制涉及两方面内容：心室重构和神经内分泌细胞因子系统的激活。心室重塑是由于一系列复杂的分子和细胞机制引起的心肌细胞结构、功能及表型的改变,包括心肌细胞凋亡、心肌细胞肥大、胚胎基因再表达及心肌细胞外基质数量和组成变化等。而神经内分泌细胞因子系统的持续过度的激活是导致心室重塑和心衰恶化的重要原因。研究证实炎性因子与心力衰竭有着密切的关系：一方面,CHF的发生发展伴随着TNF-a、IL-1、IL-6等炎性细胞因子浓度的明显增加；另一方面,各种因素诱导的上述炎性因子浓度的增加可明显加重心衰的程度,甚至可以诱发心力衰竭。由此可见,心力衰竭的发生和发展是一个“进行性”的过程,在此过程中始终有着神经内分泌的激活,这种过度的激活对低下的心室功能起代偿的同时也加重了心肌的损害,加剧了心衰的恶化。同时,循环和组织中的多种细胞因子的水平也增加,这些因子和神经内分泌激活一起,可以损害心肌细胞的活性和功能,刺激心肌纤维化,促使心脏重塑。
心力衰竭的发病机制非常复杂,随着对其发生机制的深入认识,心力衰竭的治疗决策也发生了相应的演变。其中关于阻断神经内分泌、细胞因子系统的激活和心肌重塑之间的恶性循环治疗CHF的观点已引起许多学者的关注,尽管调节神经内分泌因素治疗缺血性心衰的新药正在不断地被研制和评估,但是进一步通过抑制神经内分泌或体内其他系统改善死亡率的可能还很遥远,目前还没有确切方法能够用于干预CHF的慢性炎症状态。
中医药方法治疗慢性炎症在长期临床实践中取得良好的临床疗效,中药抗炎药理研究已从“整体-器官-细胞”水平发展到在分子、基因水平探讨中药的作用机制,逐渐呈现出涉及中药品种更多、研究范围更广、研究水平比以往更高的局面。近年来随着对CHF发病机理的进一步阐述,特别是重视慢性炎症反应在CHF发生、发展中作用,以及抗炎症治疗对于改善CHF临床症状和预后重要帮助,许多学者重新开始认识到,中医治疗CHF不仅可以采用补气、活血、利水等方法,还可以针对CHF慢性炎症反应进行干预,特别是目前西医在这方面没有很好的方法。而中药毛冬青具备清热解毒和活血通脉之功效,现代药理研究表明其具有抗炎和多种心血管药理作用,中药人参具有大补元气、生津止渴、安神等功效,现代药理研究证明其活性成分对心血管系统的多种疾病有深远的临床意义。
近年来中医界对心衰的病因病机认识趋于一致,即心衰为本虚标实之证,虚为气虚、阳虚,日久则累及心阳,涉及脾、肺、’肾,随着由气虚到阳虚,病情逐渐加重；标实为血瘀、水阻、痰饮；标本俱病、虚实夹杂,是心衰的病理特点。治疗以益气温阳治本,活血利水治标为主要的治疗方法。结合以往临床研究基础,我们认为中医治疗CHF不仅可以采用补气、活血、利水等传统方法,而且还可以采用益气活血解毒法,针对CHF的慢性炎症反应进行干预,从而改善CHF临床症状和预后。
目的：
1、临床研究：以西医规范治疗方案为对照,观察毛冬青与红参颗粒剂对慢性心力衰竭炎症状态的影响及其对慢性心力衰竭治疗的临床效果,探讨“益气活血解毒法”在慢性心力衰竭治疗中的作用。
2、实验研究：观察毛冬青对SD大鼠慢性心力衰竭炎症状态的影响,进一步验证毛冬青对于慢性心力衰竭的改善作用。
方法：
1、临床研究：①将门诊和住院慢性心力衰竭患者101例随机分为2组,每组根据不同证型分为气阴亏虚、血瘀水停证和气阳亏虚、血瘀水停证。对照组49例单纯使用西医基础治疗；治疗组52例使用西医基础治疗+中药颗粒(毛冬青、红参),同时,选取20例正常健康体检者作为正常组空白对照。②观察治疗前和4周后查血、尿、便常规、肝、肾功能、血电解质、血糖和血脂等作为安全性指标,以确定毛冬青、红参是否有毒、副作用。③治疗前和4周后检测慢性心力衰竭患者血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α).白介素-1β(IL-1β).核因子K B和B型尿钠肽(BNP)水平,并进行比较,观察治疗前后慢性心力衰竭患者炎性状态及心功能状况。④治疗前4周后进行中医症候疗效、中医症候积分、心功能疗效、中医临床症状评分、明尼苏达心衰生活质量评分等比较,评价心功能改善情况。
2、实验研究：①将60只雄性SD大鼠随机分为手术组和假手术组,手术组48只,假手术组12只。结扎腹主动脉建立心衰大鼠模型,造模成功的大鼠随机分为4组,分别为毛冬青低剂量组、毛冬青高剂量组,卡托普利组和对照组。②毛冬青低剂量组灌服毛冬青10g/kg/d；毛冬青高剂量组灌服毛冬青20g/kg/d；西药对照组灌服卡托普利100mg/kg/d；空白对照组及假手术组灌服生理盐水2ml/d。③各组均灌服2周后,行经胸超声心动图检测,将大鼠动脉血离心取血清,用Elisa酶联免疫法大鼠血清试剂盒测定白介素-1β(IL-1β).核因子kB指标并进行比较,观察毛冬青对SD大鼠慢性心力衰竭炎症状态和心功能的影响。
结果：
1、临床研究：①心衰患者血清hs-CRP、TNF-a、IL-1β、NF-κB及血浆BNP水平明显高于正常健康人群(P<0.05),且随着心力衰竭程度的加重上述指标进一步升高。②治疗后,两组患者血清hs-CRP、TNF-a、IL-1β、NF-κB等炎性因子水平、血浆BNP水平明显下降,与治疗前比较,其变化有统计学意义(P<0.05),两组治疗前后各指标的变化值比较,差别有统计学意义(P<0.05)。治疗前后两组患者不同证型间血清hs-CRP、TNF-a、IL-1β、NF-κB及血浆BNP水平的比较显示,治疗组两个证型治疗后各指标较治疗前降低,其变化有统计学意义(P<0.05)。③在西医常规治疗的基础上加入中药毛冬青和红参,能明显提高心功能疗效、明显降低中医症候积分、明尼苏达心衰生活质量评分,与对照组比较具有统计学意义(P<0.05)。
2、实验研究：经灌服中药毛冬青的CHF大鼠其血清IL-1β、NF-KB水平明显低于对照组,差别有统计学意义(P<0.05)。心脏彩超相关指标显示,灌服毛冬青的CHF大鼠左心室舒张期内径(LVDd)、左心室收缩期内径(LVDs)、射血分数(EF)、短轴缩短率(FS)与其他各组比,其组间的差别有统计学意义(P<0.05)。
结论：
1、慢性心力衰竭过程中存在免疫和炎性系统的激活,慢性心衰患者血清炎性因子hs-CRP、TNF-a、IL-1、NF-κB水平明显高于正常组。
2、慢性心衰患者血清炎性因子hs-CRP、TNF-a、IL-1、NF-κB水平随着心力衰竭程度的加重(血浆BNP水平升高)而升高,表明慢性心衰时机体炎性活动明显。
3、毛冬青和红参可以改善不同证型慢性心衰患者的心功能和中医证候,减轻临床症状,经动物实验验证毛冬青可以缓解慢性心衰患者的炎症状态。
4、益气活血解毒法可以改善慢性心力衰竭的炎症状态,改善CHF临床症状和预后。
Chronic heart failure (CHF) is a complex syndrome, defined as a variety of cardiovascular diseases due to long-term overloading, myocardial damage and contractile force weakened making ventricular dysfunction (decompensated). CHF Is the end stage of many heart disease and mortality is extremely high. The study of heart failure (HF) development mechanism has been the focus of the global cardiovascular disease prevention. For a century, the HF theory developed from heart and kidney doctrine, the hemodynamic theory, neuroendocrine hormones doctrine to the modern theory of ventricular remodeling. Modern molecular biology holds that HF pathology and physiological mechanisms involved in the activation of two aspects:ventricular remodeling and neuroendocrine cytokine system. Ventricular remodeling is due to a series of complex molecular and cellular mechanisms of myocardial cell structure, function and phenotypic changes, including cardiomyocyte apoptosis, cardiac hypertrophy, the embryonic gene expression and myocardial extracellular matrix quantity and composition changes. Sustained excessive activation of the neuroendocrine cell factor system is the important reason of ventricular remodeling and worsening HF. The study confirmed that inflammatory factors and HF have a close relationship:on the one hand, the development of CHF, along with TNF-alpha, a significant increase of the concentration of IL-1, IL-6and other proinflammatory cytokines; the other hand, a variety of factorsinduced increase in the concentration of these inflammatory factors can significantly increase the degree of HF, and can even induce HF. Thus, the occurrence and development of HF is a progressive process. In this process, always with neuroendocrine activation. This excessive activation also increased, while the low ventricular function from compensatory myocardial damage, and aggravate HF deterioration. At the same time, a variety of cytokines in the circulation and tissue levels also increased, together, these factors and neuroendocrine activation can damage the activity of myocardial cells and stimulate myocardial fibrosis, to promote cardiac remodeling.
The pathogenesis of HF is very complex, with the in-depth understanding of HF mechanism, the treatment decision making also produced corresponding change. The blocking of neuroendocrine, cytokine system activation and myocardial remodeling between the vicious spiral treatment of CHF view has attracted many scholars'attention, although the regulation of neuroendocrine factors in the treatment of ischemic HF drugs are constantly being developed and evaluated, but further by inhibiting neuroendocrine or other body systems to improve mortality may also very far away, there is no precise method can be used for CHF interventions of chronic inflammatory state.
Traditional Chinese medicine for treatment of chronic inflammation in long-term clinical practice has good clinical curative effect of traditional Chinese medicine, anti-inflammatory pharmacologic research has shifted from" overall-organ-cell" level to develop at the molecular, genetic level of traditional Chinese medicine mechanism, gradually showing relates to traditional Chinese medicine breed more, research range wider, research level higher than in the past situation. In recent years, with further elaboration of the pathogenesis of CHF, especially the emphasis on chronic inflammatory response in the CHF occurred role in the development, as well as anti-inflammatory treatment for improving the CHF clinical symptoms and the prognosis is important to help, many scholars began to re-recognize Chinese medicine treatment of CHF can be used not only the method of气and blood circulation, dieresis, can also intervene in chronic inflammatory response in CHF, in particular, the current Western medicine is no good way in this regard. And Chinese traditional medicine hairy holly has heat clearing and detoxicating and promoting blood circulation pulse-beating. Modern pharmacological research founds that it has anti-inflammatory and multiple cardiovascular pharmacological effects of ginseng tonic, with vitality, quench thirst, sedative and other effects, modern pharmacological studies have shown its active components on cardiovascular system diseases have far-reaching significance.
In recent years Chinese medicine pathogenesis of heart failure tend to be consistent, i.e. heart failure for this standard is false card, virtual as Qi, Yang long, involving the heart Yang, involving the spleen, lung, kidney, as by Qi to Yang, condition gradually worsened; Standard for water resistance, phlegm, blood stasis; specimens of all disease, the actual situation mixture, heart failure is the pathological features. Treatment of Qi and warm Yang cure, promote blood circulation and water solution as the main method of treatment. Combined with previous clinical research foundation, we suggest that Chinese medicine in the treatment of CHF can not only makes use of Qi, blood, water and other traditional methods, but also can use Detoxicating and activating blood method, according to the CHF chronic inflammatory response to intervention, thereby improving the CHF clinical symptoms and prognosis.
Objective
1. Clinical research:western medicine (WM) to standard treatment regimens for the control, the observation of hair holly and red ginseng granules on CHF inflammatory state and its effect on CHF treatment clinical effect, discuss Yiqi Huoxue Jiedu" in the treatment of CHF in rats.
2. Experimental research:Observation of hairy holly on SD rats with CHF impact of inflammatory state, further validation of hairy holly for CHF effects.
Methods
1.Clinical research:①Randomly dividing101ambulatory and hospitalized patients with CHF into2groups, each group according to the different syndromes are divided into yin deficiency, blood stasis and Yang water stop credit deficiency, blood stasis syndrome of water stop.49cases of the control group simply use the basic treatment of Western medicine; treatment group of52cases using the conventional treatment plus traditional Chinese medicine granule (hairy holly, red ginseng), at the same time, we selected20cases of normal healthy subjects served as normal control group.②Observed before treatment and4weeks after a blood test, urine, stool routine, liver, renal function, electrolyte, blood glucose and lipids as safety index, to determine whether hair holly, red ginseng, toxic side effects.③Before treatment and4weeks after the detection of CHF patients serum high sensitive C reactive protein (hs-CRP), tumor necrosis factor alpha (TNF alpha), interleukin lbeta (beta IL-1), nuclear factor kappa B and B type natriuretic peptide (BNP) level, and carries on the comparison, were observed before and after treatment for CHF in patients with inflammatory status and functional status of the heart.④The first4weeks after the treatment effect of TCM, TCM syndrome integral, heart function, traditional Chinese medicine curative effect clinical symptom score, the Minnesota heart failure score of life quality comparison, evaluation of heart function improvement.
2. Experimental research:①The60SD male rats were randomly divided into operation group and sham operation group, operation group48, sham operation group12. Ligation of abdominal aorta established heart failure rat model, modeling success of rats were randomly divided into4groups, respectively, hairy holly low dose group, high dose group of hair holly, captopril group and control group.②The hairy holly low dose group gavage hairy holly10g/kg/D; hairy holly high dose group gavage hairy holly20g/kg/D; western medicine control group fed with captopril in100mg/kg/D; blank control group and sham operation group gavage ns2ml/d.③The groups were gavage for2weeks after transthoracic ultrasound heartbeat graph, line detection, the rat arterial blood centrifuge serum, using Elisa enzyme immunoassay kit for determination of serum interleukin lbeta (beta IL-1), nuclear factor kB target and carries on the comparison, the observation of hair holly on the SD rats with CHF inflammatory status and effect of heart function.
Results
1. Clinical research:①Of heart failure in patients with serum hs-CRP, TNF A, IL-1, NF Beta Kappa B and plasma BNP levels were significantly higher than those in healthy population (P<0.05), and with the severity of heart failure the index rises further.②Two groups of patients after treatment, serum hs-CRP, TNF-A, IL-1, NF Beta Kappa B and inflammatory factor level, plasma BNP levels were significantly decreased, compared with before treatment, the changes were statistically significant (P<0.05), the two groups before and after treatment of every index value comparison, the difference has statistical significance (P<0.05). Before and after treatment in two groups of patients with different types of serum hs-CRP, TNF-A, IL-1, NF Beta Kappa B and plasma BNP level comparison shows, the treatment group two syndromes after each treatment index lower than those before therapy, the changes were statistically significant (P<0.05).③The conventional treatment of Western medicine are added on the basis of Chinese holly and red hair, can improve heart function, significantly reduce the efficacy of Chinese medicine symptom integral, the Minnesota heart failure score of life quality, compared with the control group had statistical significance (P<0.05).
2.Clinical research:Chinese traditional medicine by gavage hairy holly CHF rats serum IL-lbeta, NF kappa B levels were significantly lower than those in the control group, the difference has statistical significance (P<0.05). The heart color surpasses the related indicators, gavage of hair holly CHF rat left ventricular diastolic diameter (LVDd), left ventricular systolic diameter (LVDs), ejection fraction (EF), fractional shortening (FS) and other groups than between groups, the difference was significant (P<0.05).
Conclusion
1. CHF process in the presence of immune and inflammatory system activation in patients with CHF, serum inflammatory factor hs-CRP, TNF-A, IL-1, NF kappa B levels were significantly higher than normal group.
2.CHF patients serum inflammatory factor hs-CRP, TNF-A, IL-1, NF kappa B levels with the severity of HF (elevated plasma BNP level) and elevated during CHF, indicating systemic inflammatory activity.
3. Hairy holly and red ginseng can improve the different syndrome type of CHF in patients with cardiac function and TCM syndromes, alleviate the clinical symptoms, the animal experimental verification of hair Holly can relieve the inflammatory status in patients with CHF.
4.Detoxicating and activating blood method can improve CHF inflammatory state, improve clinical symptoms and prognosis of CHF.
心力衰竭的发病机制非常复杂,随着对其发生机制的深入认识,心力衰竭的治疗决策也发生了相应的演变。其中关于阻断神经内分泌、细胞因子系统的激活和心肌重塑之间的恶性循环治疗CHF的观点已引起许多学者的关注,尽管调节神经内分泌因素治疗缺血性心衰的新药正在不断地被研制和评估,但是进一步通过抑制神经内分泌或体内其他系统改善死亡率的可能还很遥远,目前还没有确切方法能够用于干预CHF的慢性炎症状态。
中医药方法治疗慢性炎症在长期临床实践中取得良好的临床疗效,中药抗炎药理研究已从“整体-器官-细胞”水平发展到在分子、基因水平探讨中药的作用机制,逐渐呈现出涉及中药品种更多、研究范围更广、研究水平比以往更高的局面。近年来随着对CHF发病机理的进一步阐述,特别是重视慢性炎症反应在CHF发生、发展中作用,以及抗炎症治疗对于改善CHF临床症状和预后重要帮助,许多学者重新开始认识到,中医治疗CHF不仅可以采用补气、活血、利水等方法,还可以针对CHF慢性炎症反应进行干预,特别是目前西医在这方面没有很好的方法。而中药毛冬青具备清热解毒和活血通脉之功效,现代药理研究表明其具有抗炎和多种心血管药理作用,中药人参具有大补元气、生津止渴、安神等功效,现代药理研究证明其活性成分对心血管系统的多种疾病有深远的临床意义。
近年来中医界对心衰的病因病机认识趋于一致,即心衰为本虚标实之证,虚为气虚、阳虚,日久则累及心阳,涉及脾、肺、’肾,随着由气虚到阳虚,病情逐渐加重；标实为血瘀、水阻、痰饮；标本俱病、虚实夹杂,是心衰的病理特点。治疗以益气温阳治本,活血利水治标为主要的治疗方法。结合以往临床研究基础,我们认为中医治疗CHF不仅可以采用补气、活血、利水等传统方法,而且还可以采用益气活血解毒法,针对CHF的慢性炎症反应进行干预,从而改善CHF临床症状和预后。
目的：
1、临床研究：以西医规范治疗方案为对照,观察毛冬青与红参颗粒剂对慢性心力衰竭炎症状态的影响及其对慢性心力衰竭治疗的临床效果,探讨“益气活血解毒法”在慢性心力衰竭治疗中的作用。
2、实验研究：观察毛冬青对SD大鼠慢性心力衰竭炎症状态的影响,进一步验证毛冬青对于慢性心力衰竭的改善作用。
方法：
1、临床研究：①将门诊和住院慢性心力衰竭患者101例随机分为2组,每组根据不同证型分为气阴亏虚、血瘀水停证和气阳亏虚、血瘀水停证。对照组49例单纯使用西医基础治疗；治疗组52例使用西医基础治疗+中药颗粒(毛冬青、红参),同时,选取20例正常健康体检者作为正常组空白对照。②观察治疗前和4周后查血、尿、便常规、肝、肾功能、血电解质、血糖和血脂等作为安全性指标,以确定毛冬青、红参是否有毒、副作用。③治疗前和4周后检测慢性心力衰竭患者血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α).白介素-1β(IL-1β).核因子K B和B型尿钠肽(BNP)水平,并进行比较,观察治疗前后慢性心力衰竭患者炎性状态及心功能状况。④治疗前4周后进行中医症候疗效、中医症候积分、心功能疗效、中医临床症状评分、明尼苏达心衰生活质量评分等比较,评价心功能改善情况。
2、实验研究：①将60只雄性SD大鼠随机分为手术组和假手术组,手术组48只,假手术组12只。结扎腹主动脉建立心衰大鼠模型,造模成功的大鼠随机分为4组,分别为毛冬青低剂量组、毛冬青高剂量组,卡托普利组和对照组。②毛冬青低剂量组灌服毛冬青10g/kg/d；毛冬青高剂量组灌服毛冬青20g/kg/d；西药对照组灌服卡托普利100mg/kg/d；空白对照组及假手术组灌服生理盐水2ml/d。③各组均灌服2周后,行经胸超声心动图检测,将大鼠动脉血离心取血清,用Elisa酶联免疫法大鼠血清试剂盒测定白介素-1β(IL-1β).核因子kB指标并进行比较,观察毛冬青对SD大鼠慢性心力衰竭炎症状态和心功能的影响。
结果：
1、临床研究：①心衰患者血清hs-CRP、TNF-a、IL-1β、NF-κB及血浆BNP水平明显高于正常健康人群(P<0.05),且随着心力衰竭程度的加重上述指标进一步升高。②治疗后,两组患者血清hs-CRP、TNF-a、IL-1β、NF-κB等炎性因子水平、血浆BNP水平明显下降,与治疗前比较,其变化有统计学意义(P<0.05),两组治疗前后各指标的变化值比较,差别有统计学意义(P<0.05)。治疗前后两组患者不同证型间血清hs-CRP、TNF-a、IL-1β、NF-κB及血浆BNP水平的比较显示,治疗组两个证型治疗后各指标较治疗前降低,其变化有统计学意义(P<0.05)。③在西医常规治疗的基础上加入中药毛冬青和红参,能明显提高心功能疗效、明显降低中医症候积分、明尼苏达心衰生活质量评分,与对照组比较具有统计学意义(P<0.05)。
2、实验研究：经灌服中药毛冬青的CHF大鼠其血清IL-1β、NF-KB水平明显低于对照组,差别有统计学意义(P<0.05)。心脏彩超相关指标显示,灌服毛冬青的CHF大鼠左心室舒张期内径(LVDd)、左心室收缩期内径(LVDs)、射血分数(EF)、短轴缩短率(FS)与其他各组比,其组间的差别有统计学意义(P<0.05)。
结论：
1、慢性心力衰竭过程中存在免疫和炎性系统的激活,慢性心衰患者血清炎性因子hs-CRP、TNF-a、IL-1、NF-κB水平明显高于正常组。
2、慢性心衰患者血清炎性因子hs-CRP、TNF-a、IL-1、NF-κB水平随着心力衰竭程度的加重(血浆BNP水平升高)而升高,表明慢性心衰时机体炎性活动明显。
3、毛冬青和红参可以改善不同证型慢性心衰患者的心功能和中医证候,减轻临床症状,经动物实验验证毛冬青可以缓解慢性心衰患者的炎症状态。
4、益气活血解毒法可以改善慢性心力衰竭的炎症状态,改善CHF临床症状和预后。
Chronic heart failure (CHF) is a complex syndrome, defined as a variety of cardiovascular diseases due to long-term overloading, myocardial damage and contractile force weakened making ventricular dysfunction (decompensated). CHF Is the end stage of many heart disease and mortality is extremely high. The study of heart failure (HF) development mechanism has been the focus of the global cardiovascular disease prevention. For a century, the HF theory developed from heart and kidney doctrine, the hemodynamic theory, neuroendocrine hormones doctrine to the modern theory of ventricular remodeling. Modern molecular biology holds that HF pathology and physiological mechanisms involved in the activation of two aspects:ventricular remodeling and neuroendocrine cytokine system. Ventricular remodeling is due to a series of complex molecular and cellular mechanisms of myocardial cell structure, function and phenotypic changes, including cardiomyocyte apoptosis, cardiac hypertrophy, the embryonic gene expression and myocardial extracellular matrix quantity and composition changes. Sustained excessive activation of the neuroendocrine cell factor system is the important reason of ventricular remodeling and worsening HF. The study confirmed that inflammatory factors and HF have a close relationship:on the one hand, the development of CHF, along with TNF-alpha, a significant increase of the concentration of IL-1, IL-6and other proinflammatory cytokines; the other hand, a variety of factorsinduced increase in the concentration of these inflammatory factors can significantly increase the degree of HF, and can even induce HF. Thus, the occurrence and development of HF is a progressive process. In this process, always with neuroendocrine activation. This excessive activation also increased, while the low ventricular function from compensatory myocardial damage, and aggravate HF deterioration. At the same time, a variety of cytokines in the circulation and tissue levels also increased, together, these factors and neuroendocrine activation can damage the activity of myocardial cells and stimulate myocardial fibrosis, to promote cardiac remodeling.
The pathogenesis of HF is very complex, with the in-depth understanding of HF mechanism, the treatment decision making also produced corresponding change. The blocking of neuroendocrine, cytokine system activation and myocardial remodeling between the vicious spiral treatment of CHF view has attracted many scholars'attention, although the regulation of neuroendocrine factors in the treatment of ischemic HF drugs are constantly being developed and evaluated, but further by inhibiting neuroendocrine or other body systems to improve mortality may also very far away, there is no precise method can be used for CHF interventions of chronic inflammatory state.
Traditional Chinese medicine for treatment of chronic inflammation in long-term clinical practice has good clinical curative effect of traditional Chinese medicine, anti-inflammatory pharmacologic research has shifted from" overall-organ-cell" level to develop at the molecular, genetic level of traditional Chinese medicine mechanism, gradually showing relates to traditional Chinese medicine breed more, research range wider, research level higher than in the past situation. In recent years, with further elaboration of the pathogenesis of CHF, especially the emphasis on chronic inflammatory response in the CHF occurred role in the development, as well as anti-inflammatory treatment for improving the CHF clinical symptoms and the prognosis is important to help, many scholars began to re-recognize Chinese medicine treatment of CHF can be used not only the method of气and blood circulation, dieresis, can also intervene in chronic inflammatory response in CHF, in particular, the current Western medicine is no good way in this regard. And Chinese traditional medicine hairy holly has heat clearing and detoxicating and promoting blood circulation pulse-beating. Modern pharmacological research founds that it has anti-inflammatory and multiple cardiovascular pharmacological effects of ginseng tonic, with vitality, quench thirst, sedative and other effects, modern pharmacological studies have shown its active components on cardiovascular system diseases have far-reaching significance.
In recent years Chinese medicine pathogenesis of heart failure tend to be consistent, i.e. heart failure for this standard is false card, virtual as Qi, Yang long, involving the heart Yang, involving the spleen, lung, kidney, as by Qi to Yang, condition gradually worsened; Standard for water resistance, phlegm, blood stasis; specimens of all disease, the actual situation mixture, heart failure is the pathological features. Treatment of Qi and warm Yang cure, promote blood circulation and water solution as the main method of treatment. Combined with previous clinical research foundation, we suggest that Chinese medicine in the treatment of CHF can not only makes use of Qi, blood, water and other traditional methods, but also can use Detoxicating and activating blood method, according to the CHF chronic inflammatory response to intervention, thereby improving the CHF clinical symptoms and prognosis.
Objective
1. Clinical research:western medicine (WM) to standard treatment regimens for the control, the observation of hair holly and red ginseng granules on CHF inflammatory state and its effect on CHF treatment clinical effect, discuss Yiqi Huoxue Jiedu" in the treatment of CHF in rats.
2. Experimental research:Observation of hairy holly on SD rats with CHF impact of inflammatory state, further validation of hairy holly for CHF effects.
Methods
1.Clinical research:①Randomly dividing101ambulatory and hospitalized patients with CHF into2groups, each group according to the different syndromes are divided into yin deficiency, blood stasis and Yang water stop credit deficiency, blood stasis syndrome of water stop.49cases of the control group simply use the basic treatment of Western medicine; treatment group of52cases using the conventional treatment plus traditional Chinese medicine granule (hairy holly, red ginseng), at the same time, we selected20cases of normal healthy subjects served as normal control group.②Observed before treatment and4weeks after a blood test, urine, stool routine, liver, renal function, electrolyte, blood glucose and lipids as safety index, to determine whether hair holly, red ginseng, toxic side effects.③Before treatment and4weeks after the detection of CHF patients serum high sensitive C reactive protein (hs-CRP), tumor necrosis factor alpha (TNF alpha), interleukin lbeta (beta IL-1), nuclear factor kappa B and B type natriuretic peptide (BNP) level, and carries on the comparison, were observed before and after treatment for CHF in patients with inflammatory status and functional status of the heart.④The first4weeks after the treatment effect of TCM, TCM syndrome integral, heart function, traditional Chinese medicine curative effect clinical symptom score, the Minnesota heart failure score of life quality comparison, evaluation of heart function improvement.
2. Experimental research:①The60SD male rats were randomly divided into operation group and sham operation group, operation group48, sham operation group12. Ligation of abdominal aorta established heart failure rat model, modeling success of rats were randomly divided into4groups, respectively, hairy holly low dose group, high dose group of hair holly, captopril group and control group.②The hairy holly low dose group gavage hairy holly10g/kg/D; hairy holly high dose group gavage hairy holly20g/kg/D; western medicine control group fed with captopril in100mg/kg/D; blank control group and sham operation group gavage ns2ml/d.③The groups were gavage for2weeks after transthoracic ultrasound heartbeat graph, line detection, the rat arterial blood centrifuge serum, using Elisa enzyme immunoassay kit for determination of serum interleukin lbeta (beta IL-1), nuclear factor kB target and carries on the comparison, the observation of hair holly on the SD rats with CHF inflammatory status and effect of heart function.
Results
1. Clinical research:①Of heart failure in patients with serum hs-CRP, TNF A, IL-1, NF Beta Kappa B and plasma BNP levels were significantly higher than those in healthy population (P<0.05), and with the severity of heart failure the index rises further.②Two groups of patients after treatment, serum hs-CRP, TNF-A, IL-1, NF Beta Kappa B and inflammatory factor level, plasma BNP levels were significantly decreased, compared with before treatment, the changes were statistically significant (P<0.05), the two groups before and after treatment of every index value comparison, the difference has statistical significance (P<0.05). Before and after treatment in two groups of patients with different types of serum hs-CRP, TNF-A, IL-1, NF Beta Kappa B and plasma BNP level comparison shows, the treatment group two syndromes after each treatment index lower than those before therapy, the changes were statistically significant (P<0.05).③The conventional treatment of Western medicine are added on the basis of Chinese holly and red hair, can improve heart function, significantly reduce the efficacy of Chinese medicine symptom integral, the Minnesota heart failure score of life quality, compared with the control group had statistical significance (P<0.05).
2.Clinical research:Chinese traditional medicine by gavage hairy holly CHF rats serum IL-lbeta, NF kappa B levels were significantly lower than those in the control group, the difference has statistical significance (P<0.05). The heart color surpasses the related indicators, gavage of hair holly CHF rat left ventricular diastolic diameter (LVDd), left ventricular systolic diameter (LVDs), ejection fraction (EF), fractional shortening (FS) and other groups than between groups, the difference was significant (P<0.05).
Conclusion
1. CHF process in the presence of immune and inflammatory system activation in patients with CHF, serum inflammatory factor hs-CRP, TNF-A, IL-1, NF kappa B levels were significantly higher than normal group.
2.CHF patients serum inflammatory factor hs-CRP, TNF-A, IL-1, NF kappa B levels with the severity of HF (elevated plasma BNP level) and elevated during CHF, indicating systemic inflammatory activity.
3. Hairy holly and red ginseng can improve the different syndrome type of CHF in patients with cardiac function and TCM syndromes, alleviate the clinical symptoms, the animal experimental verification of hair Holly can relieve the inflammatory status in patients with CHF.
4.Detoxicating and activating blood method can improve CHF inflammatory state, improve clinical symptoms and prognosis of CHF.
引文
[1]Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics-2007 update:A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007,115:e169-el71.
[2]林曙光.当代心脏病学新进展2011[M].北京：人民军医出版社,2011：536.
[3]Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure:A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group [J]. Circulation,2008,117:2544-2565.
[4]Report on cardiovascular diseases in China.2009. Hu Shengshou, Kong Lingzhi editors, National Center of Cardiovascular DiseasesEncyclopdia of China Publishing House.
[5]栾晓军,王国干.急性心力衰竭的流行现状和诊治进展[J].心血管病学进展,2010,31(6)：800-804.
[6]J. Julia Shin, Eman Hamad, Sandhya Murthy, et al. Heart Failure in Women [J], Clinical Cardiology,2012.35(3):172-177.
[7]Tendera M Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe European Heart Journal Supplements,2005,7 (J):J5-J9.
[8]Daniel LOISANCE. Integrated management of cardiac failure:the cardiac failure clinic [J]. Front Med,2011,5(1):20-25.
[9]Barry Greenberg. Acute decompensated heart failure-Treatments and Challenges [J]. Circulation Journal,2012,76-532-543.
[10]Greenberg BJ. Treatment of heart failure:state of the art and pros-pectives. J Cardiovasc Pharmacol,2001,38(Suppl 2):S59-S63.
[11]Hein S, Kostin S, Heling A, et al. The role of the Cytoskeleton in heart failure. Cardiovasc Res,2000,45(2):273-278.
[12]Braunwold E, Bivstow MR. Congestive heart failure:fifty years of progress. Circulation,2002,102(20):IV14-IV23.
[13]Ferguson DW. Sympathetic mechanisms in heart failure pathophysio-logical and pharmacological implication[J]. Circulation,1993,871 [Suppl 7]:68.
[14]吴立玲.心血管病理生理学[M].第1版.北京：北京医科大学出版社,2000.77.
[15]Bettencourt P, Ferreira A, Dias P, et al. L;Evaluation of brain natriuretic peptide in the diagnosis of heart failures[J]. Cardiology,2000,93 (1-2):19.
[16]Nakamura L Funayama H Yoshimura A et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. International Journal of Cardiology, 2006,106:191-195.
[17]林杰,郑德琳,李庭富.心力衰竭患者血浆脑钠素浓度与心功能的关系[J].临床心血管病杂志,2001,17(10)：454.
[18]Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapidmea-surement of B-type natriuretic peptide In the emergeney diag-nosis of heart failure[J],N Engl [J] Med,2002,347 (5): 161-167
[19]倪国华,张向阳.内皮素系统与心力衰竭[J].心血管病学进展,2007,28(2)：280-281
[20]符民桂,唐朝枢.心肌细胞肥大后信号传导通路[J].生理科学进展,2000,31(1)：19
[21]庞晓,刘红阳,席燕,等.充血性心力衰竭患者血浆—氧化氮、内皮素-1与肿瘤坏死因子的含量及其临床意义[J1.中国老年学杂志,2006,26(2)：257.
[22]Yeh CH, Chen TP, Wu YC, et al. Inhibition of NF kappaB activation with curcumin attenuates plasma inflammatorycytokines surge and cardiomyocytic apoptosis following cardi-ac ischemia/reperfusion[J]. J Surg Res,2005,125(1):109-116.
[23]Altavilla D, Deodato B,Campo GM,et al. IRFI 042, a noveldual vitamin E-like antioxidant, inhibits activation of nuclearfactor-kappaB and reduces the inflammatory response inmyo-cardial is chemia-reperfusion injury[J]. Cardiovasc Res,2000,47(3):515-528.
[24]Pelzer T, Schumam M, Neumann M, et al.17 beta-estradiol prevents programmed cell death in caniiac myocytes [J]. Biochem Biophys Res Commun,2000,268(1):192-200.
[25]DiwanA, Dibbs Z, Nemoto S, et, al. Targeted Overexpression of Noneleavable and Secreted Forms of TumorNecrosisFactor Provokes Disparate Cardiae Phenotypes [J]. Circulation, 2004,109(2):262-268
[26]Shioi-T, Matsumori-A, Kihara-Y, et al. Increased expression of interleukin-1 and monocyte chemotactic and activaing factor/monocyte chemoattra-ctant protein-1β in the hypertrophied and failing heart with pressure overload. Circ-Res,1997,81(5):664- 671.
[27]王江.细胞因子与充血性心力衰竭[J]2002,23(1)：13-16.心血管病学进展
[28]SHARMA R, COATS A J, ANKER S D. The role of inflammatory medi-ators in chronic heart failure:cytokines, nitricoxide, and endothlin-1[J].Int JCardiol,2000,72(2):175-186.
[29]Ferranti SD, Rifai N. C-reactive protein and cardiovascular disease. a review of risk prediction and in Ervention[J]. Clip Chin Acta,2002,317:1-151
[30]王芳,陈环珍,齐春雷.慢性心力衰竭患者血清NIMP-9,hs-CRP及UA检测的临床应用[J].中国医疗前沿,2010,5(2)：6-7.
[31]Parish RC, Evans JD. Inflammation in chronic heartfailure [J]. Ann Pharmacother,2008, 42:1002.
[32]李绍龙,光雪峰,白文伟.心力衰竭发病机制的研究[J].医学综述,2004,10,(12)：725-726.
[33]Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure [J]. Cochrane database of systematic reviews (Online) 2012,2:CD003838
[34]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2009 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation [J]. J Am Coll Cardiology 2009,53 (15):el-e90.
[35]Hoppe UC; Erdmann E:Digitalis in heart failure! Still applicable? [J]. Zeitschrift Fur Kardiologie,2005,94(5):307-311
[36]Adams KF, Patterson JH,0'Connor CM et al (2004) Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group (DIG) trial:a retrospective analysis. Eur Heart J 22:Abstract
[37]Qian Qi, Manning Dennis M., Ou Narith. ACEi/ARB for Systolic Heart Failure:Closing the Quality Gap With a Sustainable Intervention at an Academic Medical Center Journal of Hospital Medicine,2011,6 (3):156-160
[38]Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study [J]. Eur J Heart Fail June 2007,9(6-7):602-609.
[39]Strauss M. H, Hall A. S. Angiotensin receptor blockers may increase risk of myocardial infarction:unraveling the ARB-MI paradox [J]. Circulation August 22 2006, 114(8):838-854.
[40]Martin H. Strauss, Alistair Hall. RAS blockers:Does sex matter/Re:Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study:Marie Hudson et al [J]. European Journal of Heart Failure,2007,9: 602-609
[41]Gilbert, EM; Abraham, W T; Olsen, S; Hattler, B; White, M; Mealy, P; Larrabee, P; Bristow, M R.Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heartCirculation,1996,94:2817-2825
[42]Bellenger, NG; Rajappan, K; Rahman, SL; Lahiri, A; Raval, U; Webster, J; Murray, GD; Coats, AJS; Cleland, JGF; Pennell, DJ. Effects of carvedilol on left ventricular remodeling in chronic stable heart failure:a cardiovascular magnetic resonance studyHeart,2004,90 760-764
[43]Christer Kubon, Nisha B. Mistry, Irene Grundvold, Sigrun Halvorsen, Sverre E. Kjeldsen, Arne S. Westheim. The role of beta-blockers in the treatment of chronic heart failure [J]. Trends in Pharmacological Sciences,2011,32(4):206-212
[44]Zannad F, McMurmy JJ. KrumH。et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Ensl J Med,2011,364(1):11-21.
[45]Wolfram Grimm. Outcomes of elderly heart failure recipients of ICD and CRT[J]. International Journal of Cardiology,2008,125(2):154-160
[46]廖华,郭小梅.慢性心力衰竭诊断与治疗新进展[J].心血管病学进展,2011,32(1)：94-97.
[47]Yulong Guan, Tushar Karkhanis, Shigang Wang, Alan Rider, Steven C. Koenig, Mark S. Slaughter, Aly El Banayosy, Akif Undar. Physiologic Benefits of Pulsatile Perfusion during Mechanical Circulatory Support for the Treatment of Acute and Chronic Heart Failure in Adults [J].
[48]臧旺福,徐洪.机械辅助循环装置的应用前景[J].国际心血管病杂志,2009,36(2)：65-68.
[49]张仁福,赵科研.心脏移植现状及进展[J].医学研究杂志,2008,37(7)：4-7.
[50]J. A. Jarcho. Fear of rejection-monitoring the heart-transplant recipient, N Engl J Med,2010,362:1932-1933
[51]J. D. Christie, L. B. Edwards, A. Y. Kucheryavaya, P. Aurora, F. Dobbels, R. Kirk. The registry of the international society for heart and lung transplantation:twenty-seventh official adult lung and heart-lung transplant report 2010[J]. J Heart Lung Transplant, 2010,29:1104-1118
[52]Donndorf Peter, Strauer Bodo-Eckehard, Steinhoff Gustav. Update on cardiac stem cell therapy in heart failure [J]. Current opinion in cardiology,2012,27(2):154-160
[53]M enasche P. Stem cell the rapy fo r hear t failure:a re a rrhy thm ias a real safe tyconcern[J]. Circu lation,2009,119 (20):2735-2740.
[54]严季澜.心力衰竭.北京：人民军医出版社[M],2008：1.
[55]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：592-593.
[56]姜淑琴.心力衰竭的中医辨治[J].现代中西医结合杂志,2004,13(13)：1799.
[57]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J].中华实用中西医杂志,2005,18(23)：1780-1781.
[58]陈洁真,严夏,李俊.严夏用升清降浊法治疗慢性充血性心力衰竭经验[J].中医研究,2006,19(1)：60--61.
[59]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：392-393.
[60]张艳,宫丽鸿,于睿,等.浅谈慢性心力衰竭中医辨证康复治疗体会[J].天津中医药,2011,28(2)：131-132.
[61]周仲瑛,金妙文,吴勉华.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,2000,11(1)：13.
[62]唐蜀华,中医药治疗充血性心力衰竭的临床体会[J].上海中医药杂志,2003,37(1)：23-25.
[63]朱明军,李彬,王永霞.充血性心力衰竭中医病因病机分析[J].世界中西医结合杂志,2009,4(1)：1-2.
[64]曹雪滨,浦斌红,胡元会.充血性心力衰竭的中医辨证分型特点[J].甘肃中医学院学报,1999,16(3)：13-15.
[65]任美时.益气活血法为主治疗充血性心力衰竭57例分析[J].中医药学刊,2005,23(4)：740.
[66]张艳.慢性心衰的中医临证辨治体会[C].长春第十次全国中医心病学术年会论文集,2008：281-284.
[67]高嵩松.张艳教授对慢性心衰的中医认识与辨治[J].辽宁中医药大学学报,2008,10(10)：77-78.
[68]徐燕,杨爱东,唐靖一,等.严世芸治疗充血性心力衰竭的经验[J].上海中医药杂志,2006,40(10)：10-11.
[69]姜婕.升补宗气汤治疗老年慢性充血性心力衰竭月6例[J].河南中医.2006：26(5)：42.
[70]邓铁涛,尹克春,吴焕林.邓铁涛治疗心力衰竭经验介绍[J].江苏中医药,2002,23(7)：9-10.
[71]王发渭,郝爱真.邸玉鹏.老年心衰的中医机理与治疗探讨[J].中国中医急症,2007,16(11)：1360-1362.
[72]刘爱平.中医对慢性充血性心力衰竭的认识与治疗[J].光明中医,2007,22(9)：19-20.
[73]巩琪.心衰辨治心悟[J].中围社区医师(综合版),2007,9(10)：13.
[74]吴勉华.充血性心力衰竭中医病机探讨[J].南京中医药大学学报：自然科学版,200117(43)： 206-2 0 8.
[75]李瑞.充血性心力衰竭的中医病机探讨[J].现代中医药,2003,(1)：13-14.
[76]孙元莹,吴深涛,姜德友,等.张琪治疗充血性心衰经验介绍[J].辽宁中医杂志,2006,33(11)：1394-1395.
[77]张建伟.从肾论治慢性心衰的体会[J].世界中西医结合杂志,2007,2(4)：243-244.
[78]张持.中医对慢性充血性心力衰蝎的认识及治疗进展[J].吉林中医药,2006；26(11)：71-72.
[79]邹旭.以心脾相关理论试论心力衰竭的辨治[J].广州中医药大学学报,2007,24(5)：419-421.
[80]葛鸿庆,赵梁,郝李敏.邓铁涛教授从脾论治慢性充血性心力衰竭之经验[J].上海中医药杂志,2002,36(4)：9-10.
[81]邹旭,潘光明,林晓忠,等.以心脾相关理论试论心力衰竭的辨治[J].广州中医药大学学报,2007,24(5)：419-421.
[82]王先敏,李冬,任莉莉,等.839例慢性心力衰竭患者中医证侯分布回顾性调查研究[J].新疆医科大学学报,2011,34(7)： 673-676.
[83]张艳,宫丽鸿,于睿,等.浅谈慢性心力衰竭中医辨证康复治疗体会[J].天津中医药,2011,28(2)：131-132.
[84]黄永生.心衰论治[J].湖南中医药导报,2000,6(9)：3-5.
[85]马中夫,梁辉东,王友成.心衰病症的中医诠释及治疗[J].辽宁中医杂志,2001,28(2)：110.
[86]朴勇洙,冯大鹏,蔡宏宇.充血性心力衰竭的中医概述[J].中华实用中西医杂志.2003,3(16)：479.
[87]杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2003,25(1)：25.
[88]狄灵,梁君昭.心力衰竭辨证的临床思路与方法[J].中医杂志,2002,43(1)：67.
[89]李立志.陈可冀治疗充血性心力衰竭经验[J].中西医结合心脑血管病杂志,2006,4(2)：136-138.
[90]梁东辉.充血性心力衰竭的辨证分析及中西医结合治疗规律初探[J].实用中西医结合杂志,1997,10(11)：1069.
[91]徐重白,贾坚,吴中华.慢性心衰中医辨证分型及规范化治疗与预后的相关性[J].江西中医药,2011,42(9)：9-11.
[92]许心如.心力衰蝎的中医辨证施治[J].北京中医,1989,(3)：10.
[93]翁晓清.中西医治疗急性心肌梗塞并发泵衰蝎[J].浙江中医杂志,1994,(3)：20.
[94]袁久林.针对原发病治疗充血性心力衰竭[J].河南中医,1999,19(4)：18.
[95]杜柏,商秀洋,胡元会等.冠心病心力衰竭患者中医证型与心率变异性、醛固酮及心功能关系的研究[J].中西医结合心脑血管病杂志,20108(8)：906-908.
[96]孙艺英,李长生.充血性心力衰竭辨证分型与血浆BNP、血清CRP相关性研究[J].山东医药,2008,48(13)：53-54.
[97]刘革命,熊尚全,马成富.慢性心力衰竭中医辨证分型与血浆NO及TNF-α含量的关系[J].山东 中医杂志,2004,23(2)：71-72.
[98]王永霞,李丰涛.从痰饮论治慢性心力衰竭的思路与方法[J].中西医结合心脑血管病杂志,2011,9(1)：111-112.
[99]吕凯.健脾利水法治疗慢性心衰38例[J].中医研究,2002,15(2)：28-29.
[100]邹旭,潘光明,林晓忠.广州中医药大学学报,2007,24(5)：419-421.
[101]孙元莹,吴深涛,姜德友,等.张琪治疗充血性心衰经验介绍[J].辽宁中医杂志,2006,33(11)：1394-1395.
[102]黄天新,晏桂华.加味参附汤治疗难治性心力衰场疗效观察[J].中国中医杂志,2003,12(2)：109-137.
[103]李高兴,李南夷.益气温阳活血利水治疗充血性心力衰竭略述[J].中医药学刊,2006,24(9)：1698-1700.
[104]邹旭,吴焕林.邓铁涛教授治疗充血性心力衰竭经验选粹[J].中医药学刊,2004,4：583.
[105]张瑞华,焦增绵,马丽红,等.慢性充血性心力衰竭的中医辩证论治[J].中国医药学报,2002,17(7)：440.
[106]连林芳.辨证分型治疗充血性心力衰竭例析[J].实用中医内科杂志,2004,18(4)：301-302.
[107]王文涛.辨证分型治疗慢性心力衰竭79例报告[J].湖南中医杂志,1990,3：1.
[108]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J].中华实用中西医杂志,2005,18(23)：1780-1781.
[109]杨芬.强心利水方治疗难治性心衰30例[J].湖南中医杂志,2004,20(2)：31
[110]蒋梅先,阮小芬,徐燕.加用中药坎离煎对慢性心力衰竭患者活动耐量、生活质量及心衰加重次数的影响[J].中国中西医结合杂志,2006,26(9)：783.
[111]封海波.益气温阳法治疗心力衰竭102例[J].中西医结合心脑血管病志,2006,4(8)：708-709.
[112]田俊.参附注射液对充血性心力衰竭病人血液流变学的影响及疗效观察[J].中西医结合心脑血管病杂志.2003,1(6)：324-326.
[113]梅发光.葛根素对慢性心力衰竭患者BNP水平影响的临床研究[J].吉林中医药,2006,26(12)：17-18.
[114]李宁.参麦注射液治疗充血性心衰疗效观察[J].海南医学,2002,13(4)：85.
[115]陈勇.加味真武汤治疗慢性心衰50例临床观察[J].光明中医,2006,21(7)：34-36.
[116]傅英芝.西医的“炎症”不相等同于中医的“热证”[J].中国社区医师,2011,13(14)：5.
[117]李一明.炎症与中医寒热证关系初探[J].湖南中医杂志,1996,12(2)：75-76.
[118]Bogsty P'Poirier P, Simard S, et al. Biologicalprofiles in s^jects with long standing stable angln. Circdafion,2001,103(25):3062-3066.
[119]孙伟.从炎症因子角度谈清热解毒中药治疗冠心病的思路.硕士论文.辽宁中医药大学,6,2010.
[120]丁书文,王晓,李运仑.热毒学说在心系疾病中的构建与应用[J].山东中医药大学学报,2004,28(61)：413-416.
[121]马荫笃,马丹,马杰.中医治疗炎症临床拾零[J].江宁中医杂志,1996,23(6)：245.
[122]吴翠珍,赵爱莲,陶汉华.炎症的中医辨证论治[J].山东中医药大学学报,1999,23(1)：23-25.
[123]罗荣敬,陈洁文,周乐金,等.毛冬青甲素对心血管功能及其神经调节的影响[J].中药新药与临床药理.1995,6(4)：30-33.
[124]陈万生,韩军,李立,等.知母总多糖的抗炎作用[J].第二军医大学学报,1999,20(10)：758-760.
[125]葛卫红,李昌焊,石森林,等.荆防挥发油对炎症介质自由基及VC、胆固醇含量的影响[J].中药药理与临床,2003,19(2)：19-20.
[126]张喜平,李宗芳,刘孝恭.黄芩素的药理学研究概况[J].中国药理学通报,2001,17(6)：711-713.
[127]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2)：13-15.
[128]黄秀梅,李波,沈连忠,等.四种苦豆子生物碱对巨噬细胞产生TNF-α影响[J].中药药理与临床,2001,17(3)：12-13.
[129]周龙恩,王文杰,自金叶,等.银杏内酯B对老鼠中性白细胞花生四烯酸代谢酶和细胞内钙水平的影响[J].药学学报,2001,36(2)：92-95.
[130]程晓明,王长征,钱桂生.雷公藤抑制致敏小鼠CD4+T淋巴细胞核因子GATA3, NFAT的活性[J].免疫学杂志,2000,16(6)：417-421.
[131]Zheng X K. Feog W S. Bi Y F, et al. Determination of adenosine in Selaginella tamari. tamariscina(Beauv.)Spring by RP HPL[J]. Acta Univ Tradit Med Sin Pharmacel Shanghai(上海中医药大学学报),2003,17(2)：42-44
[132]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗[J].中华心血管病杂志.2007,35(12)：1076.
[133]Viviane MC, Johan MB, Christiaan jv. Chronic heart failure:an example of a systemic chronic in inflammatory disease resulting in cachexia[J]. Int J Cardiol,2002, (85): 33-49.
[134]Bozkun B, KribbsS, Clubb FJ, et al. Pathophysi0109ically relevant concent rations of tumor necrosis factor-a promote progressive left Ventricular dysfunction and remodeling in rats[J]. Circulation,1998,97:1382-1391.
[135]Meyer FJ, Borst MM, Zugck C, et al. Respiratory muscle dysfunction in congestive heart failure:clinical collrelation and prognostic significance[J]. Circulation,2001, 103:2153-2158.
[136]Hunt SA, Baker D W, Chim M, et al. ACC ABA Guidelines for the Evaluation and Management of Chronic heart failure in the Adult. Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 Guidelines for the Evaluations and Management of Heart Failure) [J]. Circulation,2001,104 (24):2996-3007.
[137]李伟,张振钢.抗炎症细胞因子在心力衰竭中的治疗进展[J].国际内科学杂志.2007,34(8)：471-476.
[138]郑虎占,董泽宏,佘靖。中药现代研究与应用[M].第二卷.学苑出版社,1997：1036-1044.
[139]邓文勤,钟鸣,马志玲.毛冬青化学成分.药理作用及运用研究进展[J].中国中医药.2006,4(10)：24-26.
[140]付文全.CRP在检测动脉硬化类疾病中的应用进展[J].中国医学文摘·内科学,2002,23：105.
[141]Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure [J]. Circulation 1995, 92:1479-1486.
[142]MacGowan GA, Mann DL, Kormos RI, Feldman AM, Murali S. Circulating interleukirr6 in severe heart failure [J].Am Cardiol,1997,79:1128-31.
[143]Fichtlscherer S, Rosenberer G, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102,1000-1006.
[144]Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction:does acute endothelial dysfunction provide a link?[J]. Lancet,1997,349:1391-1392.
[145]Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilation in human veins in vivo[J]. Circulation,1997,96:3042-3047.
[146]Hayaishr OR, Yamasaki Y, Katakami N, et al. Elevated Creactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes[J]. Diabetes Care,2002,25:1432-1438.
[147]Yasunari K, Maeda K, Nakamura M, et al. Oxidative stress in leukocytes is a possible 1 ink between blood pressure, blood glu-cose, and C-reactive protein[J]. Hypertension, 2002,39:777-780.
[148]刘健,马金萍,黄娇红,等.指南对老年慢性充血性心力衰竭住院患者药物治疗的影响[J].中国危重病急救医学,2010,22(10)：606-609.
[149]尹芝兰,赵水平.充血性心力衰竭患者血清c反应蛋白的变化及辛伐他汀的干预作用[J].中国医师杂志,2003,5：1225-1226.
[150]孙勇,徐宇红,超敏C反应蛋白和脑钠素在心力衰竭中的对比研究[J].实用临床医学杂志,2006,10(1)：83-84.
[151]曾兴宏.丹红注射液对慢性心力衰竭患者血浆超敏C反应蛋白影响研究[J].中国现代药物应用,2010,10(20)：8-9.
[152]Marliuez-Rumayor A, Richards AM, Bumelt JC, et al. Biology of the natriuretic peptides. Am J Cardiol,2008.101(3A):3-8.
[153]周伟君,童建菁,叶静,等.超敏c-反应蛋白与脑血管疾病危险因素的相关性研究[J].中国危重病急救医学,2007,19(6)：325-328.
[154]Chromos GP. The stress response and ilnnlune function:clinical implications. The 1999 Novera H. Spector Lecture. Ann N YAcad Sc,2000; 917:38-67.
[155]周光炎.免疫学原理.上海：上海科技文献出版社,2000,21(1)：7.
[156]Mckinney W. Bacterial lipopolysaccharide-stimulated release of tumor necrosis factor-alpha from the isolate rat heart:the effect of aprotinin and forskolin. Amsurg.2003:69(2):1314-1345.
[157]Paulus WJ. Cytokines and heart failure. Heart Fail Monit.2000,1(2):50-60.
[158]Sharma B, Coats AJ, Anker SD, et al. The role of inflammatory mediators in chronic heart failure:Cytokines, nitricoxide and endothelin-1. Int J Cardi01.2000,72(2):175-186.
[159]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemie or idiopathic dilated cardiomyopathy. Am J Cardi01.1999; 83(3): 376-382.
[160]Anker SD, VolterraniM, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Monthly journal of the Association of Physicians,1998; 91(3):199-203.
[161]Kaka D, Baumgarten G Dibbs Z et al. Nitric oxide provokes tumor necrosis factor alpha expression in adult feline myocardium through a cGMP-dependent pathway. Circulation, 2000; 102(11):1302-307.
[162]Zeng XH, Li YY. Proinflammatory cytokines and mortalit in advanced heart failure. J Heart Hailure,2002; 8(1):160.
[163]韩红梅,王宇晖.C反应蛋白、肿瘤坏死因子-α和白介素-6在充血性心力衰竭中的改变[J].疑难病杂志,2006,5(1)：41.
[164]陈白玉,李熙芹,陈晓利.肿瘤坏死因子-α、白细胞介素-1β、-6水平与充血性心力衰竭关系的临床研究[J].临床内科杂志,2006,3,23(3)：184-185.
[165]张志霞,张一昕,李国川.人参强心滴丸对充血性心力衰竭大鼠血清TNF-α和IL-1含量的影响[J].中华中医药杂志,2007,8,2(8)：549-551.
[166]Levine B, Kalman J, Mayer L, et al. Elevated Circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng I J Med,1990,323(4):236-241.
[167]Dilorio A, Ferucci Sparvieri, et al. Serum IL-1 beta levels in health and disease: A population—based study.'The InCHIANTI study'. Cytokine,2003,22(6):198-205.
[168]Thaik CM, Calderone A, Takahashi N, et al. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes [J]. J Clin Inves,1995,96:1093-9.
[169]Hinglais N, Heudes D,Nicoletti A,et al. Colocalization of myocardial fibrosis and inflammatory cells in rats[J].Lab Inves,1994,70:286-94.
[170]Pinsky D J, Cai B, Yang X, et al. The lethal effects of cytokine-einduced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beat[J]. J Clin Invest,1995,95(2):677-85.
[171]Liu S, Schreur K D. G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes[J]. Am J Physio,1995,268: C339-49.
[172]Hosenpud J D. The effects of interleukin 1 on myocardial function and metabolism [J]. Clin Immunol Immunopathol,1993,68:175-80.
[173]Pulkki K J. Cytokines and cardiomyocyte death[J]. Ann Med,1997,29:339-43.
[174]Cain BS, Meldrum DR, Dinarello CA, et al. Interleukin-1 beta synergistically depress human myocardial function[J]. Crit Care Med,1999,27(7):1309-1318.
[175]任远,黄淑田,李春燕,慢性心力衰竭病人TNF-α,IL-1β水平及相关性研究[J].中西医结合心脑血管病杂志,2008,3,6(3)：253-254。
[176]Baeuerie PA, Baltimore D. NF-K B:ten years after[J]. Cell,1996,87(1):13-20.
[177]Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F. Angiotensin H(AT1)receptor blockade reduces vascular ti ssue factor in angiotensin Ⅱ—induced cardiac vasculopathy[J]. Am J Pathol,2000,157(1):111-122.
[178]Cominacini L, Garbin V, Pasini AF, Davol iA, Campagnola M, Rigoni A. The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity[J]. CellAdhes Commun,1999,7(3):223-231.
[179]Speir E. Cytomegalovirus gene regulation by reactive oxygen species. Agents in Atherosclerosis[J]. Ann NY Acad Sci,2000,899(3):363-374.
[180]Kalm D, Baumgartenc, Dibbs z, et al. Nitric oxide provokes tumor necrosis facet-alpha expression in adult feli myocardium through a cGMP-dependent pathway[J]. Circulation, 2000,102(11):1302-1307.
[181]DeswaI A, Petersen N J, FeIdman A M, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (IVEST) [J]. Circulation,2001,103 (11):2055-2059.
[182]Bradham W S, Moe G, Wendt K A, et al. TNF-α and myocardial matrix metaIIoproteinases in heart failure relationship to LV remodeling [J]. Am J Physiol Heart Circ PhysioI, 2002,282 (4):H1288-H1295.
[183]许锦荣,陈玲,曾坚,等.老年心力衰竭患者核因子-κB与心功能的关系[J].实用医学杂志2009,25,13：2080-2081.
[184]朱茜,贾如意,高佩增.冠心病心力衰竭患者血清NF-KB水平变化及意义[J].山东医药,2010,50(23)：7-9.
[185]余利.心力衰竭患者核因子-kB活化与细胞因子分泌的相关性实验分析[J].现代医药卫生,2010,26,5,682-683.
[186]史晓敏,徐国宾,夏铁安.B型尿钠肽的生物学特性及其测定的临床应用[J].临床检验杂志,2005,23(1)：67-70.
[187]古小松,刘志华,李红霞,等.B型钠尿肽对舒张性心力衰竭的诊断价值[J].江苏医药,2008,34(1)：23-25.
[188]赵昕.B型钠尿肽的生物学特性及在心脏疾病中的应用[J].中国老年学杂志,2006,26(10)：1437-1440.
[189]宋艳秋,张辉.心衰患者血浆B-型钠尿肽水平的研究[J].心血管康复医学杂志,2011,20(4)：321-324.
[190]周建宇.B型钠尿肽评价心力衰竭的价值[J].现代中西医结合杂志,2008,17(31)：4906.
[191]顾焕,李霁,张久亮,等.益气活血法对慢性心力衰竭病人TNF-α及AngⅡ的影响[J].中西医结合心脑血管病杂志,2008,6(4)：381-382.
[192]韦育林,李楚强,陈锡龙,等.黄芪注射液对充血性心力衰竭患者细胞因子和血管紧张素的影响[J].中国临床康复,2006,10(3)：54-56.
[193]吴红金,段妹伟.参附注射液治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2009,7(5)：505-507.
[193]熊晓红.中西医结合治疗充血性心力衰竭54侧疗效观察[J].光明中医,2008,23(2)：230-231.
[195]蔺汝光.温阳益气活血法治疗慢性心力衰竭32例[J].江苏中医,中国医药学报,2002,17(7)1：440-441.
[196]唐剑林.益气活血利水法配西药治疗充血性心力衰竭48例[J].陕西中医,2005,26(11)：1135-1136.
[197]范立华,李庆海.李庆海教授治疗慢性心衰经验[J].光明中医,2009,24(5)：819-820.
[198]北京制药工业研究所.秃毛冬青叶对冠心病的药理研究[J].中草药.1980：11(8)：358-361.
[199]胡维安,陈治文.毛冬青甲素对家兔希氏束电图的影响[J].广州中医学院学报,1991,8(2)：203-206.
[200]朱莉芬,李美珠,钟伟新,等.铁冬青叶的心血管药理研究[J].中药材,1993,16(12)：29-31.
[201]丁有钦.毛冬青甲素治疗慢性充血性心力衰竭的临床观察[J].新中医,1996.28(10)：40.
[202]褚晨宇.毛冬青甲素对心肌梗塞后缺血心肌保护作用和对细胞因子影响的实验研究.硕士论文.吉林大学,31,2005.
[203]宋媛媛,李媛,张洪泉.毛冬青抗炎免疫药理作用的研究进展[J].安徽医药,2009,13(10)：1157-1159.
[204]Shioi T, Matsumori A, Kihara Y, et al Increased expression of Interleukin-10 and monocyte Chemotactic and activating Factor Failing heart with pressure overload. Circ Res,1997,81(5):664-671
[205]张志霞,张一昕,李国川,等.人参强心滴丸对充血性心力衰竭大鼠血清TNF-α和IL-1含量的影响[J].中华中医药杂志,2007,22(8)：549-551.
[206]王恒和,毛静远,张振鹏等,参麦注射液对心衰犬肿瘤坏死因子-α、IL-1β、白介素-6的影响[J].中国实验方剂学杂志,2010,7,16(7)：105-107.
[207]李彦华,王士雯,朱梅.心力衰竭大鼠组织中核因子κB的活化与细胞因子的表达[J].中华老年多器官疾病杂志,2009,10,8(5),449-451.
[2]林曙光.当代心脏病学新进展2011[M].北京：人民军医出版社,2011：536.
[3]Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure:A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group [J]. Circulation,2008,117:2544-2565.
[4]Report on cardiovascular diseases in China.2009. Hu Shengshou, Kong Lingzhi editors, National Center of Cardiovascular DiseasesEncyclopdia of China Publishing House.
[5]栾晓军,王国干.急性心力衰竭的流行现状和诊治进展[J].心血管病学进展,2010,31(6)：800-804.
[6]J. Julia Shin, Eman Hamad, Sandhya Murthy, et al. Heart Failure in Women [J], Clinical Cardiology,2012.35(3):172-177.
[7]Tendera M Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe European Heart Journal Supplements,2005,7 (J):J5-J9.
[8]Daniel LOISANCE. Integrated management of cardiac failure:the cardiac failure clinic [J]. Front Med,2011,5(1):20-25.
[9]Barry Greenberg. Acute decompensated heart failure-Treatments and Challenges [J]. Circulation Journal,2012,76-532-543.
[10]Greenberg BJ. Treatment of heart failure:state of the art and pros-pectives. J Cardiovasc Pharmacol,2001,38(Suppl 2):S59-S63.
[11]Hein S, Kostin S, Heling A, et al. The role of the Cytoskeleton in heart failure. Cardiovasc Res,2000,45(2):273-278.
[12]Braunwold E, Bivstow MR. Congestive heart failure:fifty years of progress. Circulation,2002,102(20):IV14-IV23.
[13]Ferguson DW. Sympathetic mechanisms in heart failure pathophysio-logical and pharmacological implication[J]. Circulation,1993,871 [Suppl 7]:68.
[14]吴立玲.心血管病理生理学[M].第1版.北京：北京医科大学出版社,2000.77.
[15]Bettencourt P, Ferreira A, Dias P, et al. L;Evaluation of brain natriuretic peptide in the diagnosis of heart failures[J]. Cardiology,2000,93 (1-2):19.
[16]Nakamura L Funayama H Yoshimura A et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. International Journal of Cardiology, 2006,106:191-195.
[17]林杰,郑德琳,李庭富.心力衰竭患者血浆脑钠素浓度与心功能的关系[J].临床心血管病杂志,2001,17(10)：454.
[18]Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapidmea-surement of B-type natriuretic peptide In the emergeney diag-nosis of heart failure[J],N Engl [J] Med,2002,347 (5): 161-167
[19]倪国华,张向阳.内皮素系统与心力衰竭[J].心血管病学进展,2007,28(2)：280-281
[20]符民桂,唐朝枢.心肌细胞肥大后信号传导通路[J].生理科学进展,2000,31(1)：19
[21]庞晓,刘红阳,席燕,等.充血性心力衰竭患者血浆—氧化氮、内皮素-1与肿瘤坏死因子的含量及其临床意义[J1.中国老年学杂志,2006,26(2)：257.
[22]Yeh CH, Chen TP, Wu YC, et al. Inhibition of NF kappaB activation with curcumin attenuates plasma inflammatorycytokines surge and cardiomyocytic apoptosis following cardi-ac ischemia/reperfusion[J]. J Surg Res,2005,125(1):109-116.
[23]Altavilla D, Deodato B,Campo GM,et al. IRFI 042, a noveldual vitamin E-like antioxidant, inhibits activation of nuclearfactor-kappaB and reduces the inflammatory response inmyo-cardial is chemia-reperfusion injury[J]. Cardiovasc Res,2000,47(3):515-528.
[24]Pelzer T, Schumam M, Neumann M, et al.17 beta-estradiol prevents programmed cell death in caniiac myocytes [J]. Biochem Biophys Res Commun,2000,268(1):192-200.
[25]DiwanA, Dibbs Z, Nemoto S, et, al. Targeted Overexpression of Noneleavable and Secreted Forms of TumorNecrosisFactor Provokes Disparate Cardiae Phenotypes [J]. Circulation, 2004,109(2):262-268
[26]Shioi-T, Matsumori-A, Kihara-Y, et al. Increased expression of interleukin-1 and monocyte chemotactic and activaing factor/monocyte chemoattra-ctant protein-1β in the hypertrophied and failing heart with pressure overload. Circ-Res,1997,81(5):664- 671.
[27]王江.细胞因子与充血性心力衰竭[J]2002,23(1)：13-16.心血管病学进展
[28]SHARMA R, COATS A J, ANKER S D. The role of inflammatory medi-ators in chronic heart failure:cytokines, nitricoxide, and endothlin-1[J].Int JCardiol,2000,72(2):175-186.
[29]Ferranti SD, Rifai N. C-reactive protein and cardiovascular disease. a review of risk prediction and in Ervention[J]. Clip Chin Acta,2002,317:1-151
[30]王芳,陈环珍,齐春雷.慢性心力衰竭患者血清NIMP-9,hs-CRP及UA检测的临床应用[J].中国医疗前沿,2010,5(2)：6-7.
[31]Parish RC, Evans JD. Inflammation in chronic heartfailure [J]. Ann Pharmacother,2008, 42:1002.
[32]李绍龙,光雪峰,白文伟.心力衰竭发病机制的研究[J].医学综述,2004,10,(12)：725-726.
[33]Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure [J]. Cochrane database of systematic reviews (Online) 2012,2:CD003838
[34]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2009 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation [J]. J Am Coll Cardiology 2009,53 (15):el-e90.
[35]Hoppe UC; Erdmann E:Digitalis in heart failure! Still applicable? [J]. Zeitschrift Fur Kardiologie,2005,94(5):307-311
[36]Adams KF, Patterson JH,0'Connor CM et al (2004) Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group (DIG) trial:a retrospective analysis. Eur Heart J 22:Abstract
[37]Qian Qi, Manning Dennis M., Ou Narith. ACEi/ARB for Systolic Heart Failure:Closing the Quality Gap With a Sustainable Intervention at an Academic Medical Center Journal of Hospital Medicine,2011,6 (3):156-160
[38]Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - a population study [J]. Eur J Heart Fail June 2007,9(6-7):602-609.
[39]Strauss M. H, Hall A. S. Angiotensin receptor blockers may increase risk of myocardial infarction:unraveling the ARB-MI paradox [J]. Circulation August 22 2006, 114(8):838-854.
[40]Martin H. Strauss, Alistair Hall. RAS blockers:Does sex matter/Re:Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study:Marie Hudson et al [J]. European Journal of Heart Failure,2007,9: 602-609
[41]Gilbert, EM; Abraham, W T; Olsen, S; Hattler, B; White, M; Mealy, P; Larrabee, P; Bristow, M R.Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heartCirculation,1996,94:2817-2825
[42]Bellenger, NG; Rajappan, K; Rahman, SL; Lahiri, A; Raval, U; Webster, J; Murray, GD; Coats, AJS; Cleland, JGF; Pennell, DJ. Effects of carvedilol on left ventricular remodeling in chronic stable heart failure:a cardiovascular magnetic resonance studyHeart,2004,90 760-764
[43]Christer Kubon, Nisha B. Mistry, Irene Grundvold, Sigrun Halvorsen, Sverre E. Kjeldsen, Arne S. Westheim. The role of beta-blockers in the treatment of chronic heart failure [J]. Trends in Pharmacological Sciences,2011,32(4):206-212
[44]Zannad F, McMurmy JJ. KrumH。et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Ensl J Med,2011,364(1):11-21.
[45]Wolfram Grimm. Outcomes of elderly heart failure recipients of ICD and CRT[J]. International Journal of Cardiology,2008,125(2):154-160
[46]廖华,郭小梅.慢性心力衰竭诊断与治疗新进展[J].心血管病学进展,2011,32(1)：94-97.
[47]Yulong Guan, Tushar Karkhanis, Shigang Wang, Alan Rider, Steven C. Koenig, Mark S. Slaughter, Aly El Banayosy, Akif Undar. Physiologic Benefits of Pulsatile Perfusion during Mechanical Circulatory Support for the Treatment of Acute and Chronic Heart Failure in Adults [J].
[48]臧旺福,徐洪.机械辅助循环装置的应用前景[J].国际心血管病杂志,2009,36(2)：65-68.
[49]张仁福,赵科研.心脏移植现状及进展[J].医学研究杂志,2008,37(7)：4-7.
[50]J. A. Jarcho. Fear of rejection-monitoring the heart-transplant recipient, N Engl J Med,2010,362:1932-1933
[51]J. D. Christie, L. B. Edwards, A. Y. Kucheryavaya, P. Aurora, F. Dobbels, R. Kirk. The registry of the international society for heart and lung transplantation:twenty-seventh official adult lung and heart-lung transplant report 2010[J]. J Heart Lung Transplant, 2010,29:1104-1118
[52]Donndorf Peter, Strauer Bodo-Eckehard, Steinhoff Gustav. Update on cardiac stem cell therapy in heart failure [J]. Current opinion in cardiology,2012,27(2):154-160
[53]M enasche P. Stem cell the rapy fo r hear t failure:a re a rrhy thm ias a real safe tyconcern[J]. Circu lation,2009,119 (20):2735-2740.
[54]严季澜.心力衰竭.北京：人民军医出版社[M],2008：1.
[55]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：592-593.
[56]姜淑琴.心力衰竭的中医辨治[J].现代中西医结合杂志,2004,13(13)：1799.
[57]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J].中华实用中西医杂志,2005,18(23)：1780-1781.
[58]陈洁真,严夏,李俊.严夏用升清降浊法治疗慢性充血性心力衰竭经验[J].中医研究,2006,19(1)：60--61.
[59]黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4)：392-393.
[60]张艳,宫丽鸿,于睿,等.浅谈慢性心力衰竭中医辨证康复治疗体会[J].天津中医药,2011,28(2)：131-132.
[61]周仲瑛,金妙文,吴勉华.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,2000,11(1)：13.
[62]唐蜀华,中医药治疗充血性心力衰竭的临床体会[J].上海中医药杂志,2003,37(1)：23-25.
[63]朱明军,李彬,王永霞.充血性心力衰竭中医病因病机分析[J].世界中西医结合杂志,2009,4(1)：1-2.
[64]曹雪滨,浦斌红,胡元会.充血性心力衰竭的中医辨证分型特点[J].甘肃中医学院学报,1999,16(3)：13-15.
[65]任美时.益气活血法为主治疗充血性心力衰竭57例分析[J].中医药学刊,2005,23(4)：740.
[66]张艳.慢性心衰的中医临证辨治体会[C].长春第十次全国中医心病学术年会论文集,2008：281-284.
[67]高嵩松.张艳教授对慢性心衰的中医认识与辨治[J].辽宁中医药大学学报,2008,10(10)：77-78.
[68]徐燕,杨爱东,唐靖一,等.严世芸治疗充血性心力衰竭的经验[J].上海中医药杂志,2006,40(10)：10-11.
[69]姜婕.升补宗气汤治疗老年慢性充血性心力衰竭月6例[J].河南中医.2006：26(5)：42.
[70]邓铁涛,尹克春,吴焕林.邓铁涛治疗心力衰竭经验介绍[J].江苏中医药,2002,23(7)：9-10.
[71]王发渭,郝爱真.邸玉鹏.老年心衰的中医机理与治疗探讨[J].中国中医急症,2007,16(11)：1360-1362.
[72]刘爱平.中医对慢性充血性心力衰竭的认识与治疗[J].光明中医,2007,22(9)：19-20.
[73]巩琪.心衰辨治心悟[J].中围社区医师(综合版),2007,9(10)：13.
[74]吴勉华.充血性心力衰竭中医病机探讨[J].南京中医药大学学报：自然科学版,200117(43)： 206-2 0 8.
[75]李瑞.充血性心力衰竭的中医病机探讨[J].现代中医药,2003,(1)：13-14.
[76]孙元莹,吴深涛,姜德友,等.张琪治疗充血性心衰经验介绍[J].辽宁中医杂志,2006,33(11)：1394-1395.
[77]张建伟.从肾论治慢性心衰的体会[J].世界中西医结合杂志,2007,2(4)：243-244.
[78]张持.中医对慢性充血性心力衰蝎的认识及治疗进展[J].吉林中医药,2006；26(11)：71-72.
[79]邹旭.以心脾相关理论试论心力衰竭的辨治[J].广州中医药大学学报,2007,24(5)：419-421.
[80]葛鸿庆,赵梁,郝李敏.邓铁涛教授从脾论治慢性充血性心力衰竭之经验[J].上海中医药杂志,2002,36(4)：9-10.
[81]邹旭,潘光明,林晓忠,等.以心脾相关理论试论心力衰竭的辨治[J].广州中医药大学学报,2007,24(5)：419-421.
[82]王先敏,李冬,任莉莉,等.839例慢性心力衰竭患者中医证侯分布回顾性调查研究[J].新疆医科大学学报,2011,34(7)： 673-676.
[83]张艳,宫丽鸿,于睿,等.浅谈慢性心力衰竭中医辨证康复治疗体会[J].天津中医药,2011,28(2)：131-132.
[84]黄永生.心衰论治[J].湖南中医药导报,2000,6(9)：3-5.
[85]马中夫,梁辉东,王友成.心衰病症的中医诠释及治疗[J].辽宁中医杂志,2001,28(2)：110.
[86]朴勇洙,冯大鹏,蔡宏宇.充血性心力衰竭的中医概述[J].中华实用中西医杂志.2003,3(16)：479.
[87]杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2003,25(1)：25.
[88]狄灵,梁君昭.心力衰竭辨证的临床思路与方法[J].中医杂志,2002,43(1)：67.
[89]李立志.陈可冀治疗充血性心力衰竭经验[J].中西医结合心脑血管病杂志,2006,4(2)：136-138.
[90]梁东辉.充血性心力衰竭的辨证分析及中西医结合治疗规律初探[J].实用中西医结合杂志,1997,10(11)：1069.
[91]徐重白,贾坚,吴中华.慢性心衰中医辨证分型及规范化治疗与预后的相关性[J].江西中医药,2011,42(9)：9-11.
[92]许心如.心力衰蝎的中医辨证施治[J].北京中医,1989,(3)：10.
[93]翁晓清.中西医治疗急性心肌梗塞并发泵衰蝎[J].浙江中医杂志,1994,(3)：20.
[94]袁久林.针对原发病治疗充血性心力衰竭[J].河南中医,1999,19(4)：18.
[95]杜柏,商秀洋,胡元会等.冠心病心力衰竭患者中医证型与心率变异性、醛固酮及心功能关系的研究[J].中西医结合心脑血管病杂志,20108(8)：906-908.
[96]孙艺英,李长生.充血性心力衰竭辨证分型与血浆BNP、血清CRP相关性研究[J].山东医药,2008,48(13)：53-54.
[97]刘革命,熊尚全,马成富.慢性心力衰竭中医辨证分型与血浆NO及TNF-α含量的关系[J].山东 中医杂志,2004,23(2)：71-72.
[98]王永霞,李丰涛.从痰饮论治慢性心力衰竭的思路与方法[J].中西医结合心脑血管病杂志,2011,9(1)：111-112.
[99]吕凯.健脾利水法治疗慢性心衰38例[J].中医研究,2002,15(2)：28-29.
[100]邹旭,潘光明,林晓忠.广州中医药大学学报,2007,24(5)：419-421.
[101]孙元莹,吴深涛,姜德友,等.张琪治疗充血性心衰经验介绍[J].辽宁中医杂志,2006,33(11)：1394-1395.
[102]黄天新,晏桂华.加味参附汤治疗难治性心力衰场疗效观察[J].中国中医杂志,2003,12(2)：109-137.
[103]李高兴,李南夷.益气温阳活血利水治疗充血性心力衰竭略述[J].中医药学刊,2006,24(9)：1698-1700.
[104]邹旭,吴焕林.邓铁涛教授治疗充血性心力衰竭经验选粹[J].中医药学刊,2004,4：583.
[105]张瑞华,焦增绵,马丽红,等.慢性充血性心力衰竭的中医辩证论治[J].中国医药学报,2002,17(7)：440.
[106]连林芳.辨证分型治疗充血性心力衰竭例析[J].实用中医内科杂志,2004,18(4)：301-302.
[107]王文涛.辨证分型治疗慢性心力衰竭79例报告[J].湖南中医杂志,1990,3：1.
[108]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J].中华实用中西医杂志,2005,18(23)：1780-1781.
[109]杨芬.强心利水方治疗难治性心衰30例[J].湖南中医杂志,2004,20(2)：31
[110]蒋梅先,阮小芬,徐燕.加用中药坎离煎对慢性心力衰竭患者活动耐量、生活质量及心衰加重次数的影响[J].中国中西医结合杂志,2006,26(9)：783.
[111]封海波.益气温阳法治疗心力衰竭102例[J].中西医结合心脑血管病志,2006,4(8)：708-709.
[112]田俊.参附注射液对充血性心力衰竭病人血液流变学的影响及疗效观察[J].中西医结合心脑血管病杂志.2003,1(6)：324-326.
[113]梅发光.葛根素对慢性心力衰竭患者BNP水平影响的临床研究[J].吉林中医药,2006,26(12)：17-18.
[114]李宁.参麦注射液治疗充血性心衰疗效观察[J].海南医学,2002,13(4)：85.
[115]陈勇.加味真武汤治疗慢性心衰50例临床观察[J].光明中医,2006,21(7)：34-36.
[116]傅英芝.西医的“炎症”不相等同于中医的“热证”[J].中国社区医师,2011,13(14)：5.
[117]李一明.炎症与中医寒热证关系初探[J].湖南中医杂志,1996,12(2)：75-76.
[118]Bogsty P'Poirier P, Simard S, et al. Biologicalprofiles in s^jects with long standing stable angln. Circdafion,2001,103(25):3062-3066.
[119]孙伟.从炎症因子角度谈清热解毒中药治疗冠心病的思路.硕士论文.辽宁中医药大学,6,2010.
[120]丁书文,王晓,李运仑.热毒学说在心系疾病中的构建与应用[J].山东中医药大学学报,2004,28(61)：413-416.
[121]马荫笃,马丹,马杰.中医治疗炎症临床拾零[J].江宁中医杂志,1996,23(6)：245.
[122]吴翠珍,赵爱莲,陶汉华.炎症的中医辨证论治[J].山东中医药大学学报,1999,23(1)：23-25.
[123]罗荣敬,陈洁文,周乐金,等.毛冬青甲素对心血管功能及其神经调节的影响[J].中药新药与临床药理.1995,6(4)：30-33.
[124]陈万生,韩军,李立,等.知母总多糖的抗炎作用[J].第二军医大学学报,1999,20(10)：758-760.
[125]葛卫红,李昌焊,石森林,等.荆防挥发油对炎症介质自由基及VC、胆固醇含量的影响[J].中药药理与临床,2003,19(2)：19-20.
[126]张喜平,李宗芳,刘孝恭.黄芩素的药理学研究概况[J].中国药理学通报,2001,17(6)：711-713.
[127]张金国,高东升,谭洪勇,等.黄芪注射液对老年充血性心力衰竭患者血浆促炎性细胞因子的影响[J].济宁医学院学报,2006,29(2)：13-15.
[128]黄秀梅,李波,沈连忠,等.四种苦豆子生物碱对巨噬细胞产生TNF-α影响[J].中药药理与临床,2001,17(3)：12-13.
[129]周龙恩,王文杰,自金叶,等.银杏内酯B对老鼠中性白细胞花生四烯酸代谢酶和细胞内钙水平的影响[J].药学学报,2001,36(2)：92-95.
[130]程晓明,王长征,钱桂生.雷公藤抑制致敏小鼠CD4+T淋巴细胞核因子GATA3, NFAT的活性[J].免疫学杂志,2000,16(6)：417-421.
[131]Zheng X K. Feog W S. Bi Y F, et al. Determination of adenosine in Selaginella tamari. tamariscina(Beauv.)Spring by RP HPL[J]. Acta Univ Tradit Med Sin Pharmacel Shanghai(上海中医药大学学报),2003,17(2)：42-44
[132]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗[J].中华心血管病杂志.2007,35(12)：1076.
[133]Viviane MC, Johan MB, Christiaan jv. Chronic heart failure:an example of a systemic chronic in inflammatory disease resulting in cachexia[J]. Int J Cardiol,2002, (85): 33-49.
[134]Bozkun B, KribbsS, Clubb FJ, et al. Pathophysi0109ically relevant concent rations of tumor necrosis factor-a promote progressive left Ventricular dysfunction and remodeling in rats[J]. Circulation,1998,97:1382-1391.
[135]Meyer FJ, Borst MM, Zugck C, et al. Respiratory muscle dysfunction in congestive heart failure:clinical collrelation and prognostic significance[J]. Circulation,2001, 103:2153-2158.
[136]Hunt SA, Baker D W, Chim M, et al. ACC ABA Guidelines for the Evaluation and Management of Chronic heart failure in the Adult. Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 Guidelines for the Evaluations and Management of Heart Failure) [J]. Circulation,2001,104 (24):2996-3007.
[137]李伟,张振钢.抗炎症细胞因子在心力衰竭中的治疗进展[J].国际内科学杂志.2007,34(8)：471-476.
[138]郑虎占,董泽宏,佘靖。中药现代研究与应用[M].第二卷.学苑出版社,1997：1036-1044.
[139]邓文勤,钟鸣,马志玲.毛冬青化学成分.药理作用及运用研究进展[J].中国中医药.2006,4(10)：24-26.
[140]付文全.CRP在检测动脉硬化类疾病中的应用进展[J].中国医学文摘·内科学,2002,23：105.
[141]Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure [J]. Circulation 1995, 92:1479-1486.
[142]MacGowan GA, Mann DL, Kormos RI, Feldman AM, Murali S. Circulating interleukirr6 in severe heart failure [J].Am Cardiol,1997,79:1128-31.
[143]Fichtlscherer S, Rosenberer G, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102,1000-1006.
[144]Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction:does acute endothelial dysfunction provide a link?[J]. Lancet,1997,349:1391-1392.
[145]Bhagat K, Vallance P. Inflammatory cytokines impair endothelium dependent dilation in human veins in vivo[J]. Circulation,1997,96:3042-3047.
[146]Hayaishr OR, Yamasaki Y, Katakami N, et al. Elevated Creactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes[J]. Diabetes Care,2002,25:1432-1438.
[147]Yasunari K, Maeda K, Nakamura M, et al. Oxidative stress in leukocytes is a possible 1 ink between blood pressure, blood glu-cose, and C-reactive protein[J]. Hypertension, 2002,39:777-780.
[148]刘健,马金萍,黄娇红,等.指南对老年慢性充血性心力衰竭住院患者药物治疗的影响[J].中国危重病急救医学,2010,22(10)：606-609.
[149]尹芝兰,赵水平.充血性心力衰竭患者血清c反应蛋白的变化及辛伐他汀的干预作用[J].中国医师杂志,2003,5：1225-1226.
[150]孙勇,徐宇红,超敏C反应蛋白和脑钠素在心力衰竭中的对比研究[J].实用临床医学杂志,2006,10(1)：83-84.
[151]曾兴宏.丹红注射液对慢性心力衰竭患者血浆超敏C反应蛋白影响研究[J].中国现代药物应用,2010,10(20)：8-9.
[152]Marliuez-Rumayor A, Richards AM, Bumelt JC, et al. Biology of the natriuretic peptides. Am J Cardiol,2008.101(3A):3-8.
[153]周伟君,童建菁,叶静,等.超敏c-反应蛋白与脑血管疾病危险因素的相关性研究[J].中国危重病急救医学,2007,19(6)：325-328.
[154]Chromos GP. The stress response and ilnnlune function:clinical implications. The 1999 Novera H. Spector Lecture. Ann N YAcad Sc,2000; 917:38-67.
[155]周光炎.免疫学原理.上海：上海科技文献出版社,2000,21(1)：7.
[156]Mckinney W. Bacterial lipopolysaccharide-stimulated release of tumor necrosis factor-alpha from the isolate rat heart:the effect of aprotinin and forskolin. Amsurg.2003:69(2):1314-1345.
[157]Paulus WJ. Cytokines and heart failure. Heart Fail Monit.2000,1(2):50-60.
[158]Sharma B, Coats AJ, Anker SD, et al. The role of inflammatory mediators in chronic heart failure:Cytokines, nitricoxide and endothelin-1. Int J Cardi01.2000,72(2):175-186.
[159]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemie or idiopathic dilated cardiomyopathy. Am J Cardi01.1999; 83(3): 376-382.
[160]Anker SD, VolterraniM, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Monthly journal of the Association of Physicians,1998; 91(3):199-203.
[161]Kaka D, Baumgarten G Dibbs Z et al. Nitric oxide provokes tumor necrosis factor alpha expression in adult feline myocardium through a cGMP-dependent pathway. Circulation, 2000; 102(11):1302-307.
[162]Zeng XH, Li YY. Proinflammatory cytokines and mortalit in advanced heart failure. J Heart Hailure,2002; 8(1):160.
[163]韩红梅,王宇晖.C反应蛋白、肿瘤坏死因子-α和白介素-6在充血性心力衰竭中的改变[J].疑难病杂志,2006,5(1)：41.
[164]陈白玉,李熙芹,陈晓利.肿瘤坏死因子-α、白细胞介素-1β、-6水平与充血性心力衰竭关系的临床研究[J].临床内科杂志,2006,3,23(3)：184-185.
[165]张志霞,张一昕,李国川.人参强心滴丸对充血性心力衰竭大鼠血清TNF-α和IL-1含量的影响[J].中华中医药杂志,2007,8,2(8)：549-551.
[166]Levine B, Kalman J, Mayer L, et al. Elevated Circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng I J Med,1990,323(4):236-241.
[167]Dilorio A, Ferucci Sparvieri, et al. Serum IL-1 beta levels in health and disease: A population—based study.'The InCHIANTI study'. Cytokine,2003,22(6):198-205.
[168]Thaik CM, Calderone A, Takahashi N, et al. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes [J]. J Clin Inves,1995,96:1093-9.
[169]Hinglais N, Heudes D,Nicoletti A,et al. Colocalization of myocardial fibrosis and inflammatory cells in rats[J].Lab Inves,1994,70:286-94.
[170]Pinsky D J, Cai B, Yang X, et al. The lethal effects of cytokine-einduced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beat[J]. J Clin Invest,1995,95(2):677-85.
[171]Liu S, Schreur K D. G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes[J]. Am J Physio,1995,268: C339-49.
[172]Hosenpud J D. The effects of interleukin 1 on myocardial function and metabolism [J]. Clin Immunol Immunopathol,1993,68:175-80.
[173]Pulkki K J. Cytokines and cardiomyocyte death[J]. Ann Med,1997,29:339-43.
[174]Cain BS, Meldrum DR, Dinarello CA, et al. Interleukin-1 beta synergistically depress human myocardial function[J]. Crit Care Med,1999,27(7):1309-1318.
[175]任远,黄淑田,李春燕,慢性心力衰竭病人TNF-α,IL-1β水平及相关性研究[J].中西医结合心脑血管病杂志,2008,3,6(3)：253-254。
[176]Baeuerie PA, Baltimore D. NF-K B:ten years after[J]. Cell,1996,87(1):13-20.
[177]Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F. Angiotensin H(AT1)receptor blockade reduces vascular ti ssue factor in angiotensin Ⅱ—induced cardiac vasculopathy[J]. Am J Pathol,2000,157(1):111-122.
[178]Cominacini L, Garbin V, Pasini AF, Davol iA, Campagnola M, Rigoni A. The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity[J]. CellAdhes Commun,1999,7(3):223-231.
[179]Speir E. Cytomegalovirus gene regulation by reactive oxygen species. Agents in Atherosclerosis[J]. Ann NY Acad Sci,2000,899(3):363-374.
[180]Kalm D, Baumgartenc, Dibbs z, et al. Nitric oxide provokes tumor necrosis facet-alpha expression in adult feli myocardium through a cGMP-dependent pathway[J]. Circulation, 2000,102(11):1302-1307.
[181]DeswaI A, Petersen N J, FeIdman A M, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (IVEST) [J]. Circulation,2001,103 (11):2055-2059.
[182]Bradham W S, Moe G, Wendt K A, et al. TNF-α and myocardial matrix metaIIoproteinases in heart failure relationship to LV remodeling [J]. Am J Physiol Heart Circ PhysioI, 2002,282 (4):H1288-H1295.
[183]许锦荣,陈玲,曾坚,等.老年心力衰竭患者核因子-κB与心功能的关系[J].实用医学杂志2009,25,13：2080-2081.
[184]朱茜,贾如意,高佩增.冠心病心力衰竭患者血清NF-KB水平变化及意义[J].山东医药,2010,50(23)：7-9.
[185]余利.心力衰竭患者核因子-kB活化与细胞因子分泌的相关性实验分析[J].现代医药卫生,2010,26,5,682-683.
[186]史晓敏,徐国宾,夏铁安.B型尿钠肽的生物学特性及其测定的临床应用[J].临床检验杂志,2005,23(1)：67-70.
[187]古小松,刘志华,李红霞,等.B型钠尿肽对舒张性心力衰竭的诊断价值[J].江苏医药,2008,34(1)：23-25.
[188]赵昕.B型钠尿肽的生物学特性及在心脏疾病中的应用[J].中国老年学杂志,2006,26(10)：1437-1440.
[189]宋艳秋,张辉.心衰患者血浆B-型钠尿肽水平的研究[J].心血管康复医学杂志,2011,20(4)：321-324.
[190]周建宇.B型钠尿肽评价心力衰竭的价值[J].现代中西医结合杂志,2008,17(31)：4906.
[191]顾焕,李霁,张久亮,等.益气活血法对慢性心力衰竭病人TNF-α及AngⅡ的影响[J].中西医结合心脑血管病杂志,2008,6(4)：381-382.
[192]韦育林,李楚强,陈锡龙,等.黄芪注射液对充血性心力衰竭患者细胞因子和血管紧张素的影响[J].中国临床康复,2006,10(3)：54-56.
[193]吴红金,段妹伟.参附注射液治疗冠心病心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2009,7(5)：505-507.
[193]熊晓红.中西医结合治疗充血性心力衰竭54侧疗效观察[J].光明中医,2008,23(2)：230-231.
[195]蔺汝光.温阳益气活血法治疗慢性心力衰竭32例[J].江苏中医,中国医药学报,2002,17(7)1：440-441.
[196]唐剑林.益气活血利水法配西药治疗充血性心力衰竭48例[J].陕西中医,2005,26(11)：1135-1136.
[197]范立华,李庆海.李庆海教授治疗慢性心衰经验[J].光明中医,2009,24(5)：819-820.
[198]北京制药工业研究所.秃毛冬青叶对冠心病的药理研究[J].中草药.1980：11(8)：358-361.
[199]胡维安,陈治文.毛冬青甲素对家兔希氏束电图的影响[J].广州中医学院学报,1991,8(2)：203-206.
[200]朱莉芬,李美珠,钟伟新,等.铁冬青叶的心血管药理研究[J].中药材,1993,16(12)：29-31.
[201]丁有钦.毛冬青甲素治疗慢性充血性心力衰竭的临床观察[J].新中医,1996.28(10)：40.
[202]褚晨宇.毛冬青甲素对心肌梗塞后缺血心肌保护作用和对细胞因子影响的实验研究.硕士论文.吉林大学,31,2005.
[203]宋媛媛,李媛,张洪泉.毛冬青抗炎免疫药理作用的研究进展[J].安徽医药,2009,13(10)：1157-1159.
[204]Shioi T, Matsumori A, Kihara Y, et al Increased expression of Interleukin-10 and monocyte Chemotactic and activating Factor Failing heart with pressure overload. Circ Res,1997,81(5):664-671
[205]张志霞,张一昕,李国川,等.人参强心滴丸对充血性心力衰竭大鼠血清TNF-α和IL-1含量的影响[J].中华中医药杂志,2007,22(8)：549-551.
[206]王恒和,毛静远,张振鹏等,参麦注射液对心衰犬肿瘤坏死因子-α、IL-1β、白介素-6的影响[J].中国实验方剂学杂志,2010,7,16(7)：105-107.
[207]李彦华,王士雯,朱梅.心力衰竭大鼠组织中核因子κB的活化与细胞因子的表达[J].中华老年多器官疾病杂志,2009,10,8(5),449-451.